Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1050 clinical trials
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary endpoint )

caries
neutrophil count
carcinoma
carcinoma of oropharynx
hyperhydration
  • 5 views
  • 14 Apr, 2022
  • 1 location
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Head and Neck Squamous Cell Carcinoma (HNSCC)

The is a phase 2 multi-cohort, non-randomized, open-label, multi-center study assessing the clinical benefit of SAR444245 combined with other anticancer therapies for the treatment of participants aged 18 years and older with HNSCC. This study is structured as a master protocol for the investigation of SAR444245 with other anticancer therapies. …

erbitux
cetuximab
primary tumor
oropharyngeal
cavities
  • 1 views
  • 14 Oct, 2022
  • 38 locations
A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum …

chemotherapy regimen
mk-3475
caries
docetaxel
carcinoma
  • 18 views
  • 20 Oct, 2022
  • 81 locations
Total Intravenous Anesthesia and Recurrence Free Survival

The investigators propose to compare recurrence-free survival in patients having potentially curative (Stages 1-3) surgery for esophageal cancer who will be randomly assigned to propofol-based total intravenous anesthesia or sevoflurane-based balanced general anesthesia.

opioid
cancer
esophageal cancer
surgery for esophageal cancer
esophagus cancer
  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer (AcceleRET-Lung)

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcomes when compared to a platinum chemotherapy-based regimen chosen by the Investigator from a list of standard of care treatments, as measured primarily by progression free survival (PFS), for …

pralsetinib
lung cancer
ret inhibitor
metastatic cancer
cancer treatment
  • 54 views
  • 24 Oct, 2022
  • 94 locations
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors (ReRT)

The goal of this clinical research trial is to study the use of differing investigational doses and scheduling for Proton Therapy for tumors previously treated with radiation therapy. Generally, when patients are first treated for cancer with radiation therapy, they are treated with traditional photon (or x-ray) radiation therapy, which …

  • 0 views
  • 24 Apr, 2022
  • 1 location
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer

The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in patients with Stage IIB or III squamous cell esophageal carcinoma.

blood cell count
docetaxel
carcinoma
cancer treatment
esophageal cancer
  • 15 views
  • 24 Jan, 2021
  • 1 location
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO (MOIO)

Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers. However, the optimal duration of immunotherapies is currently unknown. Our hypothesis is that a reduced dose intensity of IO could be as effective as …

bladder tumor
bevacizumab
lung cancer
triple negative breast cancer
breast cancer
  • 0 views
  • 09 Jul, 2022
  • 19 locations
Deciphering Mechanisms Underlying Cancer Immunogenicity (DECIDE)

trial. Patients with any of the following tumor types may be enrolled in the trial: Head and neck cancer, Ovarian cancer, Cervical cancer, Pre-invasive

lung cancer
cin 3
ascites
cancer
solid tumour
  • 0 views
  • 04 Oct, 2022
  • 3 locations
EXCEL: Exercise for Cancer to Enhance Living Well (EXCEL)

Project EXCEL will provide community or online exercise programs to rural and remote and under-served cancer survivors, as well as encourage participants to become life-long exercisers. Exercise is an evidence-based self-management strategy that benefits all cancer survivors. However, most cancer survivors who live in remote or rural places don't have …

primary cancer
Accepts healthy volunteers
cancer treatment
  • 0 views
  • 18 Apr, 2022
  • 1 location